Scinai Immunotherapeutics Receivables

Scinai Immunotherapeutics (SCNI) currently reports a receivables of $150K as of March 2026. That compares with $140K in the prior-year period — up 7.9% year over year. Use the charts on this page to explore Scinai Immunotherapeutics's receivables history and peer comparisons.

Scinai Immunotherapeutics's receivables increased from $140K to $150K — a 7.9% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Scinai Immunotherapeutics reported $150K in receivables as of March 2026. That compares with $140K in the prior-year period — up 7.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $150K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Scinai Immunotherapeutics, and consider following SCNI for alerts when major investors trade the stock.

Scinai Immunotherapeutics is classified in the Healthcare sector. On receivables, it currently shows $150K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SCNI with unrelated industries.